Comparison of the Clinical Outcomes of a Single Injection Adductor Canal Block with the Concomitant Use of Transdermal Buprenorphine and Continuous Adductor Canal Block after Total Knee Arthroplasty
10.4055/jkoa.2019.54.5.411
- Author:
Jung Wook HUH
1
;
Man Jun PARK
;
Young Chul KO
;
Dong Jun HA
;
Joon Hyung PARK
;
Woo Myung LEE
Author Information
1. Department of Orthopedic Surgery, Busan Medical Center, Busan, Korea. jun4128@naver.com
- Publication Type:Original Article
- Keywords:
total knee replacement;
postoperative pain;
single injection adductor canal block;
continuous adductor canal block;
transdermal buprenorphine patch
- MeSH:
Analgesia, Patient-Controlled;
Arthroplasty, Replacement, Knee;
Buprenorphine;
Catheters;
Hand;
Humans;
Incidence;
Knee Joint;
Length of Stay;
Methods;
Nausea;
Pain, Postoperative;
Passive Cutaneous Anaphylaxis;
Vomiting;
Walking
- From:The Journal of the Korean Orthopaedic Association
2019;54(5):411-417
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: To compare the clinical outcomes of single injection adductor canal block (SACB), continuous adductor canal block (CACB), and the concomitant use of transdermal buprenorphine after total knee arthroplasty (TKA). MATERIALS AND METHODS: A total of 125 patients who underwent TKA were divided into three groups and the clinical results were retrospecitively compared. Group I was comprised of patients with pain controlled by SACB (n=41). Group II consisted of patients with pain controlled by both SACB and transdermal buprenorphine (10 µg/h) (n=44). Group III contained patients with pain controlled by CACB (n=40). The visual analogue scale (VAS) was used as the pain control indicator and the patients were measured on a VAS for resting on the bed (VAS-Rest) at 12 hours, 24 hours, and 48 hours after surgery. The VAS while doing continuous passive motion (VAS-CPM) on the first and second postoperative day was also measured. In addition, the total amount of medications used (Butopahn, Tridol, and Ketorac) for the intravenous patient controlled analgesia (PCA) was counted for 48 hours after surgery. As the indicator of the functional recovery outcome, the incidence of nausea and vomiting was observed for 48 hours after surgery. The maximum knee joint flexion range and maximum walking distance on the first and second postoperative day, and the total length of stay at the hospital were compared. RESULTS: The VAS-Rest was similar in the three groups at 12 hours after surgery, but at 24 hours and 48 hours after surgery, group II and III a lower VAS-CPM and total amount of medications used for PCA than group I (p<0.05). The three groups showed a low incidence of nausea and vomiting, maximum knee joint flexion range, and similar walking distance and total length of stay at the hospital. CONCLUSION: The combination of SACB and transdermal buprenorphine has great pain control effect initially. On the other hand, it is not associated with catheter complications and it is convenient to use and safety toward the renal function. Therefore, the concomitant use of SACB and transdermal buprenorphine can be an effective pain control method after TKA.
